Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.
Foundayo launched at $149/month self-pay on April 9, 2026 — available the same day at retail pharmacies, through LillyDirect, and via telehealth providers including Ro, Amazon Pharmacy, and Weight Watchers Med+. If you've been sitting on the fence about starting a GLP-1, this is the most accessible on-ramp yet: no needles, no meal timing, 27.3 lbs average weight loss at the top dose, and the broadest same-day launch network of any GLP-1 to date.
What This Means for You
Foundayo launched at $149/month self-pay on April 9, 2026 — available the same day at retail pharmacies, through LillyDirect, and via telehealth providers including Ro, Amazon Pharmacy, and Weight Watchers Med+. If you've been sitting on the fence about starting a GLP-1, this is the most accessible on-ramp yet: no needles, no meal timing, 27.3 lbs average weight loss at the top dose, and the broadest same-day launch network of any GLP-1 to date.
Foundayo (orforglipron) is on pharmacy shelves. Eli Lilly began shipping through LillyDirect on April 6, 2026 — five days after FDA approval on April 1 — and broad retail pharmacy availability opened around April 9. Telehealth platforms including Ro, Amazon Pharmacy, Weight Watchers Med+, and GoodRx partnered with Lilly for launch-day access. By April 11, you could get a Foundayo prescription through a telehealth visit, pick it up at your local Walgreens, or have it shipped from LillyDirect — a multi-channel launch breadth that Zepbound took months to achieve after its 2023 approval. For a brand-new drug, the distribution ramp is unusually fast, which suggests Lilly has been building the infrastructure for this launch well in advance of the April 1 FDA decision.
The pricing structure is built to capture the patients compounding pharmacies had been serving. Self-pay starts at $149/month for the 3 mg starting dose, rising to $299–$349/month for higher maintenance doses (12 mg, 24 mg, 36 mg). Commercially insured patients with the Lilly savings card pay as little as $25/month. Medicare Part D enrollees have a path to approximately $50/month starting July 1, 2026. Compounded semaglutide from telehealth providers was running $100–$250/month during the shortage period; at $149/month, Foundayo is priced squarely in that range — but with FDA-verified manufacturing, standardized dosing, and documented clinical trial data behind it. The targeting is deliberate.
The differentiator Foundayo holds over Novo Nordisk’s oral semaglutide (Wegovy pill) is dosing flexibility. Oral semaglutide requires an empty stomach, minimal water, and a strict 30-minute food-free window. Miss a step and absorption drops significantly. Foundayo has no such protocol — take it whenever, with anything. In real-world adherence terms, that distinction matters. The efficacy tradeoff is real: ATTAIN-1 showed 12.4% weight loss (27.3 lbs) at the highest Foundayo dose versus 15–22% for injectables. But a pill taken consistently beats a more powerful protocol that patients abandon in week three. Dose completion matters more than peak efficacy if you never stay on the drug long enough to reach it.
The next 90 days will determine how aggressively commercial insurers add Foundayo to formulary. If major PBMs place it on preferred drug lists before summer, the savings card’s $25/month tier becomes a $0–$10 co-pay for insured patients — and that changes the volume math entirely. Watch for formulary announcements from Express Scripts, CVS Caremark, and OptumRx in May and June. That coverage decision will tell you more about Foundayo’s real-world accessibility than anything Lilly announces.
Frequently Asked Questions
Where exactly can I fill a Foundayo prescription right now?
Foundayo is available through LillyDirect (home delivery, started April 6), retail pharmacies nationwide, and telehealth platforms. Confirmed launch partners include Ro, Amazon Pharmacy, Weight Watchers Med+, and GoodRx. Major retail chains including Walgreens, Kroger, and CVS should have it in stock as of mid-April 2026 — call ahead to confirm your starting dose (3 mg) is available locally. If your pharmacy is out of stock, LillyDirect will ship within 24–48 hours with standard delivery.
Is Foundayo approved for type 2 diabetes as well as obesity?
At launch, Foundayo is FDA-approved only for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity — not as a diabetes drug. orforglipron is being studied separately for type 2 diabetes in the ATTAIN-2 trial, which showed 5.1–9.6% weight loss over 72 weeks in T2D patients. A diabetes indication would require a separate FDA application. The Novo model is instructive: Ozempic (diabetes) launched years before Wegovy (obesity). A Foundayo diabetes label likely follows in 2027 or 2028.
How does the $149/month self-pay price compare to what patients paid for compounded semaglutide?
Compounded semaglutide was running $100–$250/month from telehealth providers during the shortage period, depending on dose and source. Now that Wegovy supply has largely stabilized, FDA restrictions on compounding commercially available semaglutide have tightened. At $149/month, Foundayo’s self-pay entry price lands squarely in the range former compounding customers were paying — but it’s an FDA-approved drug with standardized manufacturing, verified dosing, and a clean clinical trial record behind it. For patients on compounded semaglutide considering a switch, Foundayo is the closest meaningful alternative.
Keep Reading
Original source
Read the full article at Eli Lilly Press Releases